Business Description
CRISPR Therapeutics AG
ISIN : CH0334081137
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.1 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -1.18 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 8.2 | |||||
Beneish M-Score | 547.8 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 735.7 | |||||
3-Year EBITDA Growth Rate | 21.2 | |||||
3-Year EPS without NRI Growth Rate | 28.4 | |||||
3-Year FCF Growth Rate | 4.1 | |||||
3-Year Book Growth Rate | 1.5 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.04 | |||||
9-Day RSI | 1.67 | |||||
14-Day RSI | 7.27 | |||||
6-1 Month Momentum % | 25.98 | |||||
12-1 Month Momentum % | 25.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 17.54 | |||||
Quick Ratio | 17.54 | |||||
Cash Ratio | 15.57 | |||||
Days Sales Outstanding | 133.18 | |||||
Days Payable | 92.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 64.8 | |||||
Operating Margin % | -60.15 | |||||
Net Margin % | -41.52 | |||||
FCF Margin % | -72.28 | |||||
ROE % | -8.39 | |||||
ROA % | -6.98 | |||||
ROIC % | -59.46 | |||||
ROC (Joel Greenblatt) % | -65.68 | |||||
ROCE % | -10.72 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 11.55 | |||||
PB Ratio | 2.29 | |||||
Price-to-Tangible-Book | 2.29 | |||||
EV-to-EBIT | -14.02 | |||||
EV-to-Forward-EBIT | -15.73 | |||||
EV-to-EBITDA | -15.4 | |||||
EV-to-Forward-EBITDA | -16.79 | |||||
EV-to-Revenue | 8.44 | |||||
EV-to-Forward-Revenue | 19.19 | |||||
EV-to-FCF | -11.46 | |||||
Price-to-Projected-FCF | 8.81 | |||||
Price-to-Net-Current-Asset-Value | 2.76 | |||||
Price-to-Net-Cash | 3.2 | |||||
Earnings Yield (Greenblatt) % | -7.13 | |||||
FCF Yield % | -5.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
CRISPR Therapeutics AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 6,484.309 | ||
EPS (TTM) (MXN) | -34.191 | ||
Beta | -0.28 | ||
Volatility % | 62.29 | ||
14-Day RSI | 7.27 | ||
14-Day ATR (MXN) | 10.568531 | ||
20-Day SMA (MXN) | 1044 | ||
12-1 Month Momentum % | 25.71 | ||
52-Week Range (MXN) | 871 - 1481.65 | ||
Shares Outstanding (Mil) | 84.88 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CRISPR Therapeutics AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CRISPR Therapeutics AG Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
CRISPR Therapeutics AG Frequently Asked Questions
What is CRISPR Therapeutics AG(MEX:CRSP)'s stock price today?
When is next earnings date of CRISPR Therapeutics AG(MEX:CRSP)?
Does CRISPR Therapeutics AG(MEX:CRSP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |